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lished data and expert clinical opinion. Conservative assump-
tions were made for geﬁtinib in the base-case analysis; namely
that geﬁtinib patients consumed the same supportive care
resources as patients treated with a combination of mitomycin,
ifosfamide and cisplatin, which is approximately 20% higher
than for BSC. RESULTS: Additional costs of geﬁtinib compared
with BSC were estimated to be approximately £5000. The addi-
tional life expectancy was estimated to be approximately 3
months giving an incremental cost per life year gained (LYG)
ratio of approximately £22k (based on mean of probabilistic
simulations). The ratio falls to approximately £17k per LYG
when equivalent palliative care costs are assumed. CONCLU-
SIONS: According to this model, the results show that geﬁtinib
is likely to be a cost-effective strategy in the UK for the treat-
ment of advanced NSCLC patients refractory to platinum and
docetaxel compared with best supportive care. The model’s con-
servative assumptions would further support this conclusion.
“Iressa” is a trademark of the AstraZeneca group of companies.
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OBJECTIVES: To systematically evaluate the impact of the
screening interval (SI) on effectiveness and cost-effectiveness of
different cervical cancer screening strategies (CCS) in Germany
using a decision analytic approach.METHODS: A decision-
analytic Markov model, was used to evaluate the longterm clin-
ical and economic outcomes of different SI (1, 2, 3, 5 years) for
the following CCS: 1) no screening; 2) conventional Papanico-
laou test (Pap); 3) liquid-based preparation (LP); 4) automated
smear analysis (AA); and 5) a combination of liquid-based
preparation and automated smear analysis. German clinical, epi-
demiological and economic data were used. Outcomes were
detected/prevented cervical cancer (CC) cases and deaths, life
expectancy, lifetime costs, and discounted incremental cost-
effectiveness ratios (ICER). A societal perspective and 3% annual
discount rate were considered. RESULTS: Medical effectiveness
increased with increasing screening frequency in all CCS. Incre-
mental effectiveness of new CCS versus Pap decreased with
increasing screening frequency and test sensitivity. Screening
every 5 years resulted in 252–699, annual screening in 3–38
detected CC cases/100,000 women. The ICER for annual Pap
versus no screening was 6600€/LYS, and for screening every 2,
3, or 5 years 2300€/LYS, 1400€/LYS, 140€/LYS, respectively.
Compared to Pap, annual screening with new CCS resulted 
in ICERs of 220,000€/LYS (AA)—1,083,000€/LYS (LP+AA).
Longer screening intervals resulted in lower ICERs. Results were
sensitive when varying values of screening test sensitivities or
screening adherence of women. CONCLUSIONS: Annual Pap
screening, the current clinical standard in Germany, is both effec-
tive and cost-effective. However, screening with new screening
techniques every 2 years may be equally effective as annual Pap,
but less costly. A reduction in screening frequency should be crit-
ically discussed within the context of improving screening adher-
ence of women.
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OBJECTIVES: Five polychemotherapy regimens: gemcitabine-
cisplatine (Gem/Cis), vinorelbine-cisplatine (Vin/Cis), docetaxel-
cisplatine (Doc/Cis), paclitaxel-cisplatine (Pac/Cis) and
paclitaxel-carboplatine (Pac/Car), are commonly used in ﬁrst-
line treatment of advanced non-small cell lung cancer. Whereas
taxanes have to be administered within a conventional day-
hospitalization setting, gemcitabine and vinorelbine could be
administrated without platinium in home-hospitalization. The
purpose of the study is to ﬁnd out which case management min-
imizes costs for the French National Health Insurance while
ensuring patient safety. METHODS: A Markov model was con-
structed in order to estimate the cost consequences of home
administrations for gemcitabine and vinorelbine chemotherapies
(without cisplatine) compared to taxanes administrated only at
hospitals. Transitional probabilities are based on Schiller (2002)
and Scagliotti (2002) published controlled trials. In all cases, no
differences in efﬁcacy were found between all regimens. A cost
minimization analysis was performed. The costs were calculated
by adding DRG costs, onerous drug costs reimbursed over DRGs
and transportation expenses. Platinium components included in
DRG costs were not added. Costs of febrile neutropenia, blood
transfusions, nausea and vomiting, diagnosis and palliative care,
were taken into account. A univariate sensitivity analysis was
performed, in order to identify the main cost drivers. RESULTS:
With the conservative assumption of no differences in therapeu-
tic efﬁcacy and no more than two home administrations per
cycle, Gem/Cis and Vin/Cis appear with annual follow-up costs
of 16,815€ and 17,200€ respectively. Taxanes (Doc/Cis, Pac/Cis
and Pac/Car) hospital administration have annual follow-up
costs of 20,800€, 22,720€, and 25,760€ respectively. CON-
CLUSION: When the patient’s safety and his will to receive
chemotherapy at home are met in an environment where equiv-
alent efﬁcacy exists between chemotherapy regimens, an eco-
nomic analysis can quantify the ﬁnancial consequences on the
French Health Insurance, of the drug choice made by prescribers.
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OBJECTIVES: Gemcitabine/cisplatin (GC) is one of several
novel chemotherapy regimens available for the treatment of non-
small cell lung cancer. An economic cost-minimisation analysis
using a phase III randomized clinical trial was performed to 
evaluate the relative total cost of treatment of GC with other
novel agent regimens in Taiwan. METHODS: The analysis was
based upon the trial published by Schiller et al. (2002) with GC,
paclitaxel/cisplatin (PC), paclitaxel/carboplatin (PCA) and doc-
etaxel/cisplatin (DC) as treatment arms. The economic evalua-
tions were conducted using the retrospective model in European
countries published by Schiller et al. (2004). Taiwan costs were
drawn from Taiwan National Health Insurance Reimbursement
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database of year 2001. RESULTS: The economic evaluation indi-
cated the costing of chemotherapy drug acquisition per patient
for GC is NTD 128,872 (USD$3816) (1USD = $33.77NTD) and
NTD 151,293 (USD$4480), NTD 251,126 (USD$7436), NTD
143,377 (USD$4246) for PC, PCA and DC, respectively. The
average total cost per patient for GC is NTD 162,984
(USD$4826). This was lower than those treated with PC, PCA
and DC with average savings of NTD 33,389 (USD$989), NTD
116,962 (USD$3463) and NTD 20,611 (USD$610) per patient,
respectively. These results proved robust in light of a univariate
sensitivity analysis. CONCLUSIONS: GC was associated with
lower total treatment costs than PC, PCA and DC from the per-
spective of the national health reimbursement of Taiwan. Given
similar efﬁcacy ﬁndings in these studies, GC is offering cost-
savings potential in the treatment of advanced NSCLC is sup-
ported. The limitations of this research include the complex of
the disease; the conventional chemotherapy regimens as well as
the cost of approaches for adverse events management are dif-
ferent by each health care provider.
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OBJECTIVES: The efﬁciency of a radical prostatectomy (RP)
and a permanent seed implantation (PSI) was compared as ther-
apeutic alternatives in the treatment of stage T1-T2 prostate
cancer in Germany. METHODS: The comparison between PSI
and RP was made by a cost-effectiveness-analysis assisted by the
software DATA Professional. Costs, efﬁcacy and tolerability of
both alternatives were the evaluation parameters. Data for prob-
abilities of success and rates of adverse effects (AE) were taken
from international studies. Success of therapy was deﬁned as PSA
(prostate-speciﬁc antigen)-progression free survival within 7
years. Therapy failure was deﬁned as PSA levels >0.2ng/ml in
two successive readings for RP cases and three consecutive rising
PSA levels for PSI patients. Applying the perspective of the statu-
tory health insurance (SHI) PSI is more cost-effective compared
with RP. All direct (medical) costs of therapy of prostate cancer,
of therapy failure and of treatment of AE, reimbursed by SHI in
Germany, were considered. In accordance with the Hannover
consensus guidelines, costs were discounted at 5% pa.
RESULTS: Total costs amounted to 7691€ for a PSI and 8715€
for a RP. Effectiveness-adjusted costs at similar effectiveness rates
(0.76 PSI, 0.76 RP) amounted to 10,120€ for PSI and 11,468€
for RP. PSI therefore dominates the RP alternative. Two sensi-
tivity-analyses were conducted by varying probabilities of
success for each alternative. PSI dominates RP as long as prob-
ability of success of PSI is not lower than 0.68 or for RP not
higher than 0.85. CONCLUSIONS: Considering the perspective
of SHI, the therapy of stage T1-T2 prostate cancer with 
permanent seed implantation is more cost-effective than radical
prostatectomy.
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